Roots Analysis identifies top 5 wearable injector companies
Roots Analysis has named five key players in the wearable injector market. These devices facilitate biologics delivery and the advancement of home-based care.
Roots Analysis has identified five companies leading the development and manufacturing of wearable injectors. These devices enable subcutaneous administration of biologics and high-viscosity therapeutics over extended periods, offering a more convenient and less invasive alternative to traditional intravenous infusions.
The adoption of wearable injectors is rising, particularly for managing oncology, autoimmune disorders, and chronic diseases. They enhance patient comfort and support home-based care. Technological advancements have integrated smart features, including Bluetooth monitoring and mobile app connectivity, for personalized remote patient monitoring.
The market is projected for substantial growth, driven by the increasing prevalence of chronic diseases and an expanding pipeline of biologic drugs. A greater preference for self-administration and decentralized healthcare, coupled with pharmaceutical companies' investments in patient-centric platforms, are expected to accelerate market expansion.
According to Roots Analysis' study, the top five companies include Becton Dickinson (BD), Enable Injections, Insulet, West Pharmaceutical Services, and Ypsomed. These companies were selected based on their device portfolios and recent initiatives.